Block Drug Co. Inc.
Division of GlaxoSmithKline PLC
Latest From Block Drug Co. Inc.
In Vivo presents another installment of our quarterly review of dealmaking--in this case November 2000-January 2001. Our data comes from Windhover's Strategic Transactions Database. We include medical device financings by industry segment and by deal type; medical device M&A; diagnostic financings and alliances by product category; pharma and biotech alliances by technology segment; pharma and biotech alliances by deal type, and pharma and biotech financings by market segment and therapeutic category.
In this era of pharmaceutical industry consolidation, large pharmaceutical companies, and in particular the newly-merged, taking stock of their increasing bulk, have been heard to say that they will drop products in development that don't have the potential to achieve at least $500 million in revenues. Big pharmas are also looking more critically at their small products already on the market. For these large companies, small products could prove to be a distraction that diverts resources away from potential blockbusters, the kinds of products that the companies will need to grow by 15% a year going forward. In theory, then, as pharmaceutical companies up-average product portfolios in favor of high-revenue producers and prune away redundant or non-strategic products in the aftermath of mergers, many more commercializable products should become available for licensing than ever before. That is the hope, anyway, of a handful of new specialty pharmaceutical companies formed to acquire on-the-market products with the aim of growing their sales through a variety of strategies. These companies avoid product development risk but bear risk of a different sort. To be successful, they must be able to continually acquire products that can grow, and not pay too much for them.
With the downsizing following mergers, some new companies are being formed by transplanted teams of executives. A team of ex-Wellcome executives have started an HIV-focused company pursuing a business Glaxo Wellcome probably couldn’t tackle. Is this the new shape of pharmaceutical start-ups?
- Therapeutic Areas
- North America
- Parent & Subsidiaries
- GlaxoSmithKline PLC
- Senior Management
Melvin Kopp, SVP, CFO
Thomas Block, Pres.
Stephen McAuliffe, VP, Mktg., Consumer Products Div.
Michael Alfano, PhD, SVP, Research & Technology
Allan H Johnston, VP, Licensing
- Contact Info
Block Drug Co. Inc.
Phone: (201) 434-3000
257 Cornelison Ave.
Jersey City, NJ 07302-3198
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.